Evidence map›Paper›PMID 34590333›Full record

ArticleStatistics in medicine2021

A comparison of methods for analyzing a binary composite endpoint with partially observed components in randomized controlled trials.

Tra My Pham, Ian R White, Brennan C Kahan, Tim P Morris, Simon J Stanworth, Gordon Forbes

Open access · hybridAbstract read
In one paragraph

Article in Statistics in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tra My PhamMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.ORCID 0000-0003-0528-6303
Ian R WhiteMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.ORCID 0000-0002-6718-7661
Brennan C KahanMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.ORCID 0000-0001-9957-0844
Tim P MorrisMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.ORCID 0000-0001-5850-3610
Simon J StanworthNHS Blood & Transplant, Oxford University Hospitals and the University of Oxford, Oxford, UK.
Gordon ForbesBiostatistics & Health Informatics Department, King's College London, London, UK.
MRC Clinical Trials Unit at UCL · GBKing's College London · GBNHS Blood and Transplant · GB

Funding

Department of Health NF-SI-0617-10120Medical Research Council MC_UU_00004/07Medical Research Council MC_UU_12023/21Medical Research Council MR/JO16020/1
6 · The paper itself

Abstract

Composite endpoints are commonly used to define primary outcomes in randomized controlled trials. A participant may be classified as meeting the endpoint if they experience an event in one or several components (eg, a favorable outcome based on a composite of being alive and attaining negative culture results in trials assessing tuberculosis treatments). Partially observed components that are not missing simultaneously complicate the analysis of the composite endpoint. An intuitive strategy frequently used in practice for handling missing values in the components is to derive the values of the composite endpoint from observed components when possible, and exclude from analysis participants whose composite endpoint cannot be derived. Alternatively, complete record analysis (CRA) (excluding participants with any missing components) or multiple imputation (MI) can be used. We compare a set of methods for analyzing a composite endpoint with partially observed components mathematically and by simulation, and apply these methods in a reanalysis of a published trial (TOPPS). We show that the derived composite endpoint can be missing not at random even when the components are missing completely at random. Consequently, the treatment effect estimated from the derived endpoint is biased while CRA results without the derived endpoint are valid. Missing at random mechanisms require MI of the components. We conclude that, although superficially attractive, deriving the composite endpoint from observed components should generally be avoided. Despite the potential risk of imputation model mis-specification, MI of missing components is the preferred approach in this study setting.

Indexed as

Data Interpretation, StatisticalComputer SimulationHumansRandomized Controlled Trials as Topiccompatibilitycomposite endpointsmissing datamultiple imputationRCTs

Identifiers

PMID34590333
PMCPMC7614656
OpenAlexW3204069683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.